Immunomodulatory Macrophages Enable E-MNC Therapy for Radiation-Induced Salivary Gland Hypofunction.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Leukocytes, Mononuclear* ; CD28 Antigens*; Mice ; Animals ; Salivary Glands ; Recombinant Proteins ; Macrophages

A newly developed therapy using effective-mononuclear cells (E-MNCs) is reportedly effective against radiation-damaged salivary glands (SGs) due to anti-inflammatory and revascularization effects. However, the cellular working mechanism of E-MNC therapy in SGs remains to be elucidated. In this study, E-MNCs were induced from peripheral blood mononuclear cells (PBMNCs) by culture for 5-7 days in medium supplemented with five specific recombinant proteins (5G-culture). We analyzed the anti-inflammatory characteristics of macrophage fraction of E-MNCs using a co-culture model with CD3/CD28-stimulated PBMNCs. To test therapeutic efficacy in vivo, either E-MNCs or E-MNCs depleted of CD11b-positive cells were transplanted intraglandularly into mice with radiation-damaged SGs. Following transplantation, SG function recovery and immunohistochemical analyses of harvested SGs were assessed to determine if CD11b-positive macrophages contributed to tissue regeneration. The results indicated that CD11b/CD206-positive (M2-like) macrophages were specifically induced in E-MNCs during 5G-culture, and Msr1- and galectin3-positive cells (immunomodulatory macrophages) were predominant. CD11b-positive fraction of E-MNCs significantly inhibited the expression of inflammation-related genes in CD3/CD28-stimulated PBMNCs. Transplanted E-MNCs exhibited a therapeutic effect on saliva secretion and reduced tissue fibrosis in radiation-damaged SGs, whereas E-MNCs depleted of CD11b-positive cells and radiated controls did not. Immunohistochemical analyses revealed HMGB1 phagocytosis and IGF1 secretion by CD11b/Msr1-positive macrophages from both transplanted E-MNCs and host M2-macrophages. Thus, the anti-inflammatory and tissue-regenerative effects observed in E-MNC therapy against radiation-damaged SGs can be partly explained by the immunomodulatory effect of M2-dominant macrophage fraction.

Stem Cells Transl Med. 2019 Mar;8(3):271-284. (PMID: 30394698)
J Am Heart Assoc. 2014 Jun 25;3(3):e000743. (PMID: 24965023)
PLoS One. 2013 Apr 24;8(4):e61632. (PMID: 23637870)
Cell Rep. 2017 Apr 11;19(2):225-234. (PMID: 28402847)
Radiother Oncol. 2016 May;119(2):250-8. (PMID: 26900094)
Int Immunopharmacol. 2020 Sep;86:106761. (PMID: 32629409)
Cancer Lett. 2015 Nov 28;368(2):156-63. (PMID: 25911239)
J Natl Cancer Inst Monogr. 2019 Aug 1;2019(53):. (PMID: 31425600)
Nat Med. 2017 Jun;23(6):723-732. (PMID: 28394332)
Eur Arch Otorhinolaryngol. 2017 Feb;274(2):1129-1138. (PMID: 27812787)
Food Saf (Tokyo). 2016 Sep 17;4(3):61-73. (PMID: 32231908)
Int J Biochem Cell Biol. 2011 Jan;43(1):80-7. (PMID: 20933096)
Mol Ther. 2015 Jul;23(7):1189-1200. (PMID: 25896247)
Sci Rep. 2019 Oct 31;9(1):15752. (PMID: 31673085)
Front Physiol. 2021 Aug 06;12:705838. (PMID: 34421643)
Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1040-6. (PMID: 19117692)
Front Immunol. 2022 Jul 08;13:928134. (PMID: 35880175)
Guo Ji Fang She Yi Xue He Yi Xue Za Zhi. 2016 Mar;40(2):91-99. (PMID: 27331198)
J Cell Mol Med. 2020 Jan;24(1):214-226. (PMID: 31657123)
Semin Immunopathol. 2018 Nov;40(6):523-538. (PMID: 30206661)
PLoS One. 2015 Nov 03;10(11):e0141862. (PMID: 26529411)
PLoS One. 2009;4(3):e4663. (PMID: 19252741)
J Cell Physiol. 2018 Sep;233(9):6425-6440. (PMID: 29319160)
Stem Cell Res Ther. 2019 Oct 17;10(1):304. (PMID: 31623661)
Crit Rev Oral Biol Med. 2003;14(3):213-25. (PMID: 12799324)
J Oral Sci. 2004 Jun;46(2):119-25. (PMID: 15287546)
J Tissue Eng. 2022 Apr 7;13:20417314221085645. (PMID: 35422983)
J Radiat Res. 2018 Sep 1;59(5):541-546. (PMID: 29947767)
Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Mar;117(3):335-342.e1. (PMID: 24528792)
Medicine (Baltimore). 2020 Jun 26;99(26):e20788. (PMID: 32590759)
Diabetes. 2013 Sep;62(9):3207-17. (PMID: 23670975)
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):579-86. (PMID: 20638195)
Oral Oncol. 2017 Mar;66:64-74. (PMID: 28249650)
Oral Oncol. 2007 Oct;43(9):843-68. (PMID: 17600755)
Blood. 2010 Aug 5;116(5):829-40. (PMID: 20404134)
Front Cell Dev Biol. 2022 May 26;10:896591. (PMID: 35721513)
Semin Radiat Oncol. 2013 Oct;23(4):273-80. (PMID: 24012341)
J Neurosci. 2007 Mar 7;27(10):2596-605. (PMID: 17344397)
Cancer. 2006 Dec 1;107(11):2525-34. (PMID: 17078052)
Int J Environ Res Public Health. 2020 Aug 31;17(17):. (PMID: 32878050)
J Dent Res. 2022 Dec;101(13):1645-1653. (PMID: 36408969)
Stem Cells. 2017 Jan;35(1):97-105. (PMID: 27406006)
Radiother Oncol. 2019 Sep;138:9-16. (PMID: 31136962)
Int Immunol. 2017 Feb 1;29(2):59-70. (PMID: 28338748)
Circulation. 2018 Oct 30;138(18):2021-2035. (PMID: 29967195)

Keywords: cell therapy; macrophage; peripheral blood mononuclear cells; radiation-induced damage; salivary gland

0 (CD28 Antigens)
0 (Recombinant Proteins)

Date Created: 20230706 Date Completed: 20230707 Latest Revision: 20230718

20231215

PMC10216929

10.3390/cells12101417

37408251